In three MONALEESA phase 3 trials, addition of ribociclib to adjuvant endocrine therapy improved...
Read More
According to the first results of the EMERALD trial, elacestrant, the first oral selective...
Read More
Primary analysis of the KEYNOTE-522 trial shows a statistically significant and clinically...
Read More
A next-generation technology allows the study of protein expression at the single-cell level and...
Read More
Although adjuvant therapy with CDK4/6 inhibitors has shown to benefit patients with...
Read More
The use of multigene sequencing as a therapeutic decision tool improved the outcomes for patients...
Read More
The pathways leading to CDK4/6 inhibitor resistance are not yet clear. Using a technique called...
Read More
Development of breast cancer-related lymphedema is not equally distributed between races. Black...
Read More
Efficacy of second-line treatment option for patients with ER-positive/HER2-negative metastatic...
Read More
The phase 3 BioItaLEE trial demonstrates that pre-treatment circulating tumor DNA (ctDNA) and...
Read More
Adjuvant treatment with the PARP inhibitor olaparib showed beneficial effects for patients with...
Read More
Both patients with heavily pre-treated HR-positive/HER2-negative, HER2-mutated, metastatic breast...
Read More
Long-term use of tamoxifen is associated with an increased risk for the development of uterine...
Read More
In pre-menopausal women with early-stage, ER-positive breast cancer, adjuvant ovarian suppression...
Read More
Taxane with or without anthracycline reduces the recurrence rate of early-stage breast cancer. A...
Read More
Both adjuvant therapy with trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) have...
Read More
The phase 3 RxPONDER trial evaluated the benefit of adjuvant chemotherapy followed by endocrine...
Read More
Among patients with HR-positive breast cancer treated with an aromatase inhibitor plus...
Read MoreClonal hematopoiesis of indeterminate potential (CHIP) was related to decreased risk of Alzheimer’s disease (AD) and AD neuropathological changes. Mutated hematopoietic stem cells were detected in the brains of CHIP carriers....
Read MoreTherapy de-escalation in patients with acute lymphoblastic leukemia (ALL) and a low-risk minimal residual disease (MRD) profile was safe, 10-year follow-up results of the UKALL 2003 trial show. Patients with a high-risk MRD...
Read More
